WVE-003 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 8 | ハンチントン病 | 8 |
8. ハンチントン病
臨床試験数 : 242 / 薬物数 : 205 - (DrugBank : 62) / 標的遺伝子数 : 85 - 標的パスウェイ数 : 159
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2020-004556-15-NL (EUCTR) | 01/03/2022 | 11/02/2022 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-003 Administered Intrathecally in Patients With Huntington’s Disease | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-003 Administered Intrathecally in Patients With Huntington’s Disease | Huntington's Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: WVE-003 Product Code: WVE-003 INN or Proposed INN: WVE-003 | Wave Life Sciences UK Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 36 | Phase 1;Phase 2 | France;Canada;Spain;Poland;Denmark;Australia;Germany;Netherlands;United Kingdom;Switzerland;Italy | ||
| 2 | EUCTR2020-004556-15-IT (EUCTR) | 13/12/2021 | 06/10/2021 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-003 Administered Intrathecally in Patients With Huntington’s Disease | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-003 Administered Intrathecally in Patients With Huntington’s Disease - - | Huntington's Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: WVE-003 Product Code: [WVE-003] INN or Proposed INN: WVE-003 | Wave Life Sciences UK Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 36 | Phase 1;Phase 2 | France;Canada;Spain;Poland;Denmark;Australia;Germany;United Kingdom;Italy | ||
| 3 | NCT05032196 (ClinicalTrials.gov) | September 6, 2021 | 18/8/2021 | Study of WVE-003 in Patients With Huntington's Disease | A Multicenter, Randomized, Double-blind, Placebo Controlled, Phase 1b/2a Study of WVE-003 Administered Intrathecally in Patients With Huntington's Disease (SELECT-HD) | Huntington Disease | Drug: WVE-003 | Wave Life Sciences Ltd. | NULL | Recruiting | 25 Years | 60 Years | All | 36 | Phase 1/Phase 2 | Australia;Canada;Denmark;France;Germany;Italy;Poland;Spain;United Kingdom |
| 4 | EUCTR2020-004556-15-ES (EUCTR) | 18/08/2021 | 23/06/2021 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-003 Administered Intrathecally in Patients With Huntington’s Disease | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-003 Administered Intrathecally in Patients With Huntington’s Disease | Huntington's Disease;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: WVE-003 Product Code: WVE-003 INN or Proposed INN: WVE-003 | Wave Life Sciences UK Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 36 | Phase 1;Phase 2 | France;Canada;Poland;Spain;Denmark;Australia;Germany;United Kingdom;Italy | ||
| 5 | EUCTR2020-004556-15-DK (EUCTR) | 21/06/2021 | 12/04/2021 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-003 Administered Intrathecally in Patients With Huntington’s Disease | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-003 Administered Intrathecally in Patients With Huntington’s Disease | Huntington's Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: WVE-003 Product Code: WVE-003 INN or Proposed INN: WVE-003 | Wave Life Sciences UK Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 36 | Phase 1;Phase 2 | France;Canada;Spain;Poland;Australia;Denmark;Netherlands;Germany;Switzerland;United Kingdom;Italy | ||
| 6 | EUCTR2020-004556-15-FR (EUCTR) | 31/05/2021 | 01/04/2021 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-003 Administered Intrathecally in Patients With Huntington’s Disease | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-003 Administered Intrathecally in Patients With Huntington’s Disease | Huntington's Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: WVE-003 Product Code: WVE-003 INN or Proposed INN: WVE-003 | Wave Life Sciences UK Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 36 | Phase 1;Phase 2 | France;Canada;Spain;Poland;Denmark;Australia;Germany;United Kingdom | ||
| 7 | EUCTR2020-004556-15-PL (EUCTR) | 18/05/2021 | 23/02/2021 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-003 Administered Intrathecally in Patients With Huntington’s Disease | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-003 Administered Intrathecally in Patients With Huntington’s Disease | Huntington's Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: WVE-003 Product Code: WVE-003 INN or Proposed INN: WVE-003 | Wave Life Sciences UK Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 36 | Phase 1;Phase 2 | France;Canada;Spain;Poland;Denmark;Australia;Germany;Italy;United Kingdom | ||
| 8 | EUCTR2020-004556-15-DE (EUCTR) | 12/03/2021 | 25/01/2021 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-003 Administered Intrathecally in Patients With Huntington’s Disease | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-003 Administered Intrathecally in Patients With Huntington’s Disease | Huntington's Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: WVE-003 Product Code: WVE-003 INN or Proposed INN: WVE-003 | Wave Life Sciences UK Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 24 | Phase 1;Phase 2 | France;Canada;Spain;Poland;Denmark;Australia;Netherlands;Germany;United Kingdom;Switzerland;Italy |